company background image
HBPC.F logo

Helix BioPharma OTCPK:HBPC.F Stock Report

Last Price

US$0.14

Market Cap

US$28.8m

7D

-7.0%

1Y

n/a

Updated

28 Mar, 2024

Data

Company Financials

Helix BioPharma Corp.

OTCPK:HBPC.F Stock Report

Market Cap: US$28.8m

HBPC.F Stock Overview

Helix BioPharma Corp. operates as an immune-oncology company in Canada.

HBPC.F fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Helix BioPharma Corp. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Helix BioPharma
Historical stock prices
Current Share PriceCA$0.14
52 Week HighCA$0.15
52 Week LowCA$0.14
Beta-0.71
1 Month Changen/a
3 Month Changen/a
1 Year Changen/a
3 Year Change-79.74%
5 Year Change-40.13%
Change since IPO-94.86%

Recent News & Updates

Recent updates

Shareholder Returns

HBPC.FUS BiotechsUS Market
7D-7.0%0.9%0.4%
1Yn/a10.3%28.8%

Return vs Industry: Insufficient data to determine how HBPC.F performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how HBPC.F performed against the US Market.

Price Volatility

Is HBPC.F's price volatile compared to industry and market?
HBPC.F volatility
HBPC.F Average Weekly Movementn/a
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: HBPC.F has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine HBPC.F's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a9Jacek Antashttps://www.helixbiopharma.com

Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging.

Helix BioPharma Corp. Fundamentals Summary

How do Helix BioPharma's earnings and revenue compare to its market cap?
HBPC.F fundamental statistics
Market capUS$28.82m
Earnings (TTM)-US$4.39m
Revenue (TTM)n/a

0.0x

P/S Ratio

-6.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
HBPC.F income statement (TTM)
RevenueCA$0
Cost of RevenueCA$0
Gross ProfitCA$0
Other ExpensesCA$5.94m
Earnings-CA$5.94m

Last Reported Earnings

Oct 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.027
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did HBPC.F perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.